Literature DB >> 31904707

A Multicenter Randomized Controlled Trial of Intensive Group Therapy for Tobacco Treatment in HIV-Infected Cigarette Smokers.

Cassandra A Stanton1, Princy N Kumar2, Alyson B Moadel, Chinazo O Cunningham3,4, Clyde B Schechter4, Ryung S Kim, Jonathan Shuter3.   

Abstract

BACKGROUND: Tobacco use has emerged as the leading killer of persons living with HIV (PLWH) in the United States. Little is known about the efficacy of tobacco treatment strategies in PLWH.
DESIGN: Randomized controlled trial comparing Positively Smoke Free (PSF), an intensive group therapy intervention targeting HIV-infected smokers, to brief advice to quit. All participants were offered a 12-week supply of nicotine patches.
METHODS: A cohort of 450 PLWH smokers, recruited from HIV-care centers in the Bronx, New York, and Washington, DC, were randomized 1:1 into the PSF or brief advice to quit conditions. PSF is an 8-session program tailored to address the needs and concerns of HIV-infected smokers and delivered by a trained smoking cessation counselor and PLWH ex-smoker peer pair. The primary outcome was biochemically confirmed, 7-day point-prevalence abstinence at 6 months.
RESULTS: In the intention to treat analysis, PSF condition subjects had nearly double the quit rate of controls, 13% vs. 6.6% [odds ratio = 2.10 (95% confidence interval = 1.10 to 4.14), P = 0.04], at 3 months, but no significant difference in abstinence was observed at 6 months. PSF participants exhibited lower nicotine dependence and higher self-efficacy to resist smoking temptations at both 3 and 6 months compared with controls. Lower educational attainment, current cocaine use, past use of nicotine patches, and higher distress tolerance were significant predictors of continued smoking at 6 months.
CONCLUSIONS: These findings suggest a role for group therapy among tobacco treatments for PLWH smokers, but strategies to augment the durability of early effects are needed.

Entities:  

Mesh:

Year:  2020        PMID: 31904707     DOI: 10.1097/QAI.0000000000002271

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

Review 1.  Harm reduction for smokers living with HIV.

Authors:  Jonathan Shuter; Krishna P Reddy; Emily P Hyle; Cassandra A Stanton; Nancy A Rigotti
Journal:  Lancet HIV       Date:  2021-08-27       Impact factor: 16.070

2.  Randomized Trial of a Web-Based Tobacco Treatment and Online Community Support for People With HIV Attempting to Quit Smoking Cigarettes.

Authors:  Jonathan Shuter; Geetanjali Chander; Amanda L Graham; Ryung S Kim; Cassandra A Stanton
Journal:  J Acquir Immune Defic Syndr       Date:  2022-06-01       Impact factor: 3.771

3.  Tobacco Use and Treatment of Tobacco Dependence Among People With Human Immunodeficiency Virus: A Practical Guide for Clinicians.

Authors:  Krishna P Reddy; Gina R Kruse; Stephanie Lee; Jonathan Shuter; Nancy A Rigotti
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

4.  Adapting a tobacco cessation treatment intervention and implementation strategies to enhance implementation effectiveness and clinical outcomes in the context of HIV care in Vietnam: a case study.

Authors:  Donna Shelley; Gloria Guevara Alvarez; Trang Nguyen; Nam Nguyen; Lloyd Goldsamt; Charles Cleland; Yesim Tozan; Jonathan Shuter; Mari Armstrong-Hough
Journal:  Implement Sci Commun       Date:  2022-10-17

5.  Behavioral and Genetic Factors Associated with Successful Long-Term Cessation in Persons with HIV Who Smoke Cigarettes.

Authors:  Jonathan Shuter; H Dean Hosgood; Ryung S Kim; Kenny Ye; Cristina Montagna; Jidong Shan; Andrea H Weinberger
Journal:  J Smok Cessat       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.